We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
- Authors
Khorashad, Jamshid S; de Lavallade, Hugues; Apperley, Jane F; Milojkovic, Dragana; Reid, Alistair G; Bua, Marco; Szydlo, Richard; Olavarria, Eduardo; Kaeda, Jaspal; Goldman, John M; Marin, David
- Abstract
Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 29, p4806
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.9953